What happened
Celltrion Pharm filed provisional (unaudited) separate results for Q1 2026: revenue of US$91.5M (+17.42% year on year), operating profit of US$8.93M (+20.16% year on year) and net income of US$6.1M (+20.44% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$91.5M |
|---|---|
| Revenue vs a year earlier | +17.42% |
| Operating profit | US$8.93M |
| Net income | US$6.1M |
| Period | Q1 2026 (separate) |
| Filed | 2026-05-06, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260506900554 → open original filing |
Source: DART. Information only, not investment advice.